Article Per Year (5 Year)
p-Index From 2021 - 2026
0.23
P-Index
This Author published in this journals
All Journal Journal of Endocrinology, Tropical Medicine, and Infectious Disease (JETROMI)
Grace Nikensari
Universitas Sumatera Utara
Health Professions Immunology & microbiology Medicine & Pharmacology Public Health

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
Characteristics of Heart Failure Patients with Reduced Left Ventricular Ejection Fraction (HFrEF) Using Angiotensin Receptor-Neprilysin Inhibitors (ARNI) Compared to Angiotensin Converting Enzyme-Inhibitor (ACE-I)/Angiotensin Receptor Blocker (ARB) Therap Grace Nikensari; Cut Aryfa Andra; Ali Nafiah Nasution; Anggia Chairuddin Lubis; Kamal Kharrazi Ilyas
Journal of Endocrinology, Tropical Medicine, and Infectious Disease (JETROMI) Vol. 8 No. 1 (2026): Journal of Endocrinology, Tropical Medicine, and Infectious Disease (JETROMI)
Publisher : TALENTA Publisher, Universitas Sumatera Utara

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.32734/jetromi.v8i1.25086

Abstract

BACKGROUND: Heart failure with reduced ejection fraction (HFrEF) remains a major cause of cardiovascular morbidity. While guideline-directed medical therapy, including Angiotensin Receptor Neprylisin Inhibitor (ARNI) dan Angiotensin Converting Enzyme-Inhibitor (ACE-I)/Angiotensin Receptor Blocker (ARB), is well-established, real-world clinical profiling of these patients in Indonesia remains limited. OBJECTIVES: To evaluate and compare the baseline clinical, demographic, and pharmacological characteristics of HFrEF patients receiving ARNI versus ACE/ARB therapies at Haji Adam Malik Hospital, Medan. METHODS: This cross-sectional, descriptive study was conducted at the integrated heart center polyclinic from August to December 2025. We consecutively enrolled 50 eligible HFrEF outpatients, consisting of 25 patients receiving ACE/ARB and 25 patients receiving ARNI therapies. Data regarding demographics, medical history, and medication records were extracted and analyzed. RESULTS: The cohort had an overall mean age of 57.6 years and was predominantly male (78%). The primary underlying etiology was Ischemic Cardiomyopathy (86%). Key comorbidities included hypertension (54%) and diabetes mellitus (32%). Overall analysis demonstrated that demographic and clinical parameters, including age, systolic blood pressure, and comorbidities, were not significantly different between patients receiving ACE/ARB and those receiving ARNI (all p > 0.05). CONCLUSION: HFrEF patients in our center are predominantly male with an ischemic etiology and a significant burden of cardiometabolic comorbidities. Baseline clinical profiles are highly comparable between those prescribed ARNI and ACE/ARB therapies, providing valuable real-world data for the optimization of HFrEF management.
Co-Authors Ali Nafiah Nasution Andra, Cut Aryfa Kamal Kharrazi Ilyas Lubis, Anggia Chairuddin